2-乙氧基-5-三氟甲基苯硼酸 | 850593-10-1

• 物质功能分类: 化学试剂 - 有机试剂 - 硼酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-乙氧基-5-三氟甲基苯硼酸
• 中文别名: 2-乙氧基-5-三氟甲基苯基硼酸
• 英文名称: (2-ethoxy-5-trifluoromethylphenyl)boronic acid
• 英文别名: 2-Ethoxy-5-trifluoromethylphenylboronic acid；[2-ethoxy-5-(trifluoromethyl)phenyl]boronic acid
• CAS: 850593-10-1
• 化学式: C₉H₁₀BF₃O₃
• mdl: MFCD06801695
• 分子量: 233.983
• InChiKey: IOCXELVDHLDNMQ-UHFFFAOYSA-N

物化性质

• 熔点：
  100-104
• 沸点：
  337.4±52.0 °C(Predicted)
• 密度：
  1.31±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.61
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  6

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2931900090
• 危险性防范说明：
  P233,P260,P261,P264,P271,P280,P302+P352,P304,P304+P340,P305+P351+P338,P312,P321,P332+P313,P337+P313,P340,P362,P403,P403+P233,P405,P501
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
2-Ethoxy-5-trifluoromethylphenylboronic acid
Product Name:
Synonyms: 2-Ethoxy-5-(trifluoromethyl)phenylboronic acid

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
2-Ethoxy-5-trifluoromethylphenylboronic acid
Ingredient name:
CAS number: 850593-10-1

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C9H10BF3O3
Molecular weight: 234.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-benzyloxy-4-(4-trifluoromethoxyphenyl)-1H-pyrazole 、 2-乙氧基-5-三氟甲基苯硼酸 在 吡啶 、 copper diacetate 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 48.0h， 生成 1-[2-Ethoxy-5-(trifluoromethyl)phenyl]-3-phenylmethoxy-4-[4-(trifluoromethoxy)phenyl]pyrazole
  参考文献：
  名称：

  [EN] GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE
  [FR] ANTAGONISTES DU RÉCEPTEUR DE GLUCAGON, COMPOSTIONS ET PROCÉDÉ D'UTILISATION DE CES COMPOSÉS

  摘要：

  本发明涉及一般式(I)的化合物，其中环A、环B、R1、R2、R3、Z和L1彼此独立选择，并如本文所定义，涉及包含该化合物的组合物，以及将该化合物用作胰高血糖素受体拮抗剂并用于治疗或预防2型糖尿病及相关疾病的方法。

  公开号：

  WO2009140342A1

文献信息

• NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS
  申请人：Carroll William A.

  公开号：US20100041720A1

  公开（公告）日：2010-02-18

  Disclosed herein are cannabinoid receptor ligands of formula (I) wherein Y, X 1 , X 2 , X 3 , R 1 , and R 2 are as defined in the specification. Compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

  本文揭示了公式（I）的大麻素受体配体，其中Y、X1、X2、X3、R1和R2如规范中所定义。还公开了包含这些化合物的组合物，以及使用这些化合物和组合物治疗疾病和疾病的方法。
• 6-Phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
  申请人：Cai Jiaqiang

  公开号：US20070179138A1

  公开（公告）日：2007-08-02

  The present invention relates to 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives having the general Formula I wherein each of the substituents is given the definition as set forth in the specification and claims, pharmaceutical compositions comprising the same as well as to the use of these derivatives for the preparation of a medicament for the treatment of cathepsin S and/or cathepsin K related diseases such as osteoporosis, atherosclerosis, inflammation and immune disorders, such as rheumatoid arthritis, and chronic pain, such as neuropathic pain.

  本发明涉及具有通式I的6-苯基-1H-咪唑[4,5-c]吡啶-4-碳腈衍生物，其中每个取代基的定义如规范和权利要求中所述，包括含有这些衍生物的药物组合物，以及利用这些衍生物制备用于治疗与cathepsin S和/或cathepsin K相关疾病的药物，如骨质疏松症、动脉粥样硬化、炎症和免疫紊乱，如类风湿性关节炎，以及慢性疼痛，如神经病理性疼痛。
• Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives
  申请人：Cephalon, Inc.

  公开号：US20130296312A1

  公开（公告）日：2013-11-07

  This application relates, in part, to compounds of the general Formula I and/or salts thereof, wherein X, R 1A , R 1B , R 2 , R 3 , R 4 , and R 5 are as defined herein. The application also relates to compositions and methods of inhibiting at least JAK2 in subjects in recognized need thereof for the treatment of diseases or disorders for which inhibition of at least JAK2 is indicated.

  该应用程序部分涉及一般式I化合物和/或其盐，其中X、R1A、R1B、R2、R3、R4和R5的定义如本文所述。该应用程序还涉及组合物和方法，用于抑制至少在有需要的患者中的JAK2，以治疗需要抑制至少JAK2的疾病或疾病。
• Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
  申请人：Curry Matthew A.

  公开号：US08501936B2

  公开（公告）日：2013-08-06

  This application relates to compounds of the general Formula I and salts thereof, wherein X, R1A, R1B, R2, R3, R4, and R5 are as defined herein. The application also relates to compositions and methods of treatment of hyperproliferative diseases or disorders.

  本申请涉及一般式I的化合物及其盐，其中X、R1A、R1B、R2、R3、R4和R5的定义如本文所述。本申请还涉及治疗过度增殖性疾病或障碍的组合物和方法。
• WO2007/80191
  申请人：——

  公开号：——

  公开（公告）日：——